CST, 77087T, DOT1L (D1W4Z) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying DOT1L. Validated for WB,IP,ChIP,C&R,C&T. Available in 2 sizes. Highly specific and rigorously validated in-house, DOT1L (D1W4Z) Rabbit Monoclonal Antibody (CST #77087) is ready to ship. Product Usage Information For optimal ChIP and ChIP-seq results, use 10 μl of antibody and 10 μg of chromatin (approximately 4 x 10 6 cells) per IP. This antibody has been validated using SimpleChIP ® Enzymatic Chromatin IP Kits. The CUT&RUN dilution was determined using CUT&RUN Assay Kit # 86652 . The CUT&Tag dilution was determined using CUT&Tag Assay Kit # 77552 . Western Blotting: 1:1000 Immunoprecipitation: 1:200 Chromatin IP: 1:50 CUT&RUN: 1:50 CUT&Tag: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation, Chromatin IP, CUT&RUN, CUT&Tag Specificity / Sensitivity DOT1L (D1W4Z) Rabbit Monoclonal Antibody recognizes endogenous levels of total DOT1L protein. Species Reactivity: Human, Monkey Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro459 of human DOT1L protein. Background DOT1-like protein (DOT1L), also known as Lysine N-methyltransferase 4 (KMT4), is a histone methyltransferase that functions to mono-, di-, and tri-methylate histone H3 on lysine 79, a histone modification that is associated with active transcription and plays a role in DNA damage response, cell cycle regulation, and embryonic stem cell development (1). DOT1L is required for the initiation and maintenance of mixed lineage leukemia (MLL)-rearranged leukemias, and selective DOT1L inhibitors such as EP2-5676 show remarkable anti-tumor effects in MLL-rearranged leukemias (2,3). Multiple studies have also implicated DOT1L in solid tumor cancers such as breast cancer, where DOT1L induces neoplastic transformation of immortalized breast cancer cells and promotes tumor initiation and growth. Overexpression of DOT1L is associated with poor prognosis in breast cancer, and selective DOT1L inhibitors are able to suppress proliferation and migration of breast cancer cells (4-6). Alternate Names DKFZp586P1823; DOT1; DOT1 like histone H3K79 methyltransferase; DOT1 like histone lysine methyltransferase; DOT1-like histone methyltransferase; DOT1-like protein; DOT1-like, histone H3 methyltransferase; DOT1-like, histone H3 methyltransferase (S. cerevisiae); DOT1L; H3-K79-HMTase; Histone H3-K79 methyltransferase; histone methyltransferase DOT1L; Histone-lysine N-methyltransferase, H3 lysine-79 specific; KIAA1814; KMT4; Lysine N-methyltransferase 4 Specification REACTIVITY: H Mk SENSITIVITY: Endogenous MW (kDa): 185 Source/Isotype: Rabbit IgG